Roche, Affitech Ink Development Deal For Oncology-Targeted Monoclonal Antibodies
This article was originally published in The Pink Sheet Daily
Executive Summary
Roche intends to commercialize cancer antibodies developed using Affitech’s phagemid technology, firms say.
You may also be interested in...
Abraxis Cited Again for cGMP Violations At Illinois Facility
Firm tells “The Pink Sheet” DAILY it has taken “aggressive actions” in response to issues mentioned in a late 2006 FDA warning letter.
GSK, Genmab Set “Ambitious” Development Plan For HuMax-CD20
GSK signs record $2.1 billion deal with Genmab to commercialize the CD20 antibody for leukemia and rheumatoid arthritis indications.
Solvay's Androgel REMS Proposal May Need More Restrictions - Cmte.
Solvay may need a more restrictive Risk Evaluation and Mitigation Strategy for AndroGel 1% to adequately warn against the danger of secondary transfer of the testosterone gel, according to some members of FDA's Pediatric Advisory Committee